Geode Capital Management
DNA icon

Geode Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Geode Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Buy
1,222,016
+212,654
+21% +$1.78M ﹤0.01% 2437
2026
Q1 		$6.19M Buy
1,009,362
+9,762
+1% +$81.2K ﹤0.01% 2637
2025
Q4 		$8.31M Buy
999,600
+191,240
+24% +$2.06M ﹤0.01% 2498
2025
Q3 		$11.8M Sell
808,360
-129,223
-14% -$1.55M ﹤0.01% 2324
2025
Q2 		$10.5M Buy
937,583
+479,154
+105% +$3.71M ﹤0.01% 2334
2025
Q1 		$2.61M Buy
458,429
+21,404
+5% +$218K ﹤0.01% 2942
2024
Q4 		$4.29M Buy
437,025
+20,394
+5% +$175K ﹤0.01% 2812
2024
Q3 		$3.4M Buy
416,631
+33,824
+9% +$339K ﹤0.01% 2940
2024
Q2 		$5.12M Sell
382,807
-164,457
-30% -$4.91M ﹤0.01% 2704
2024
Q1 		$25.4M Buy
547,264
+20,068
+4% +$1.04M ﹤0.01% 1778
2023
Q4 		$35.6M Buy
527,196
+26,230
+5% +$1.61M ﹤0.01% 1553
2023
Q3 		$36.3M Buy
500,966
+67,724
+16% +$5.41M ﹤0.01% 1444
2023
Q2 		$32.2M Buy
433,242
+91,082
+27% +$5.39M ﹤0.01% 1537
2023
Q1 		$18.2M Buy
342,160
+47,784
+16% +$3.03M ﹤0.01% 1868
2022
Q4 		$19.9M Buy
294,376
+42,624
+17% +$3.92M ﹤0.01% 1781
2022
Q3 		$31.4M Sell
251,752
-48,767
-16% -$5.81M ﹤0.01% 1422
2022
Q2 		$28.6M Buy
300,519
+55,521
+23% +$6.77M ﹤0.01% 1500
2022
Q1 		$39.5M Buy
244,998
+885
+0.4% +$172K ﹤0.01% 1412
2021
Q4 		$81.1M Buy
+244,113
New +$116M 0.01% 950

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management's DNA Position: Q2 2026 in Review

Geode Capital Management increased its Ginkgo Bioworks (DNA) stake by 21% in Q2 2026, buying an estimated $1.78M and bringing the position to 1,222,016 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2437.

Geode Capital Management first reported a position in DNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $81.1M in Q4 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Geode Capital Management held 1,222,016 shares of Ginkgo Bioworks worth $12.1M as of Q2 2026.
  • Geode Capital Management bought 212,654 Ginkgo Bioworks shares in Q2 2026, an estimated $1.78M.
  • Ginkgo Bioworks made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2437 holding.
  • Geode Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Ginkgo Bioworks position peaked at $81.1M in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.